KDM1A and cancer: INCB059872 is a novel LSD1 inhibitor,239 and a phase I/II clinical study was started to evaluate its safety, tolerability and efficacy in patients with advanced malignant tumors in 2016, which was conducted in 4 parts (ClinicalTrials.gov Identifier: NCT02712905).